Renal Impairment / Chronic Kidney Disease Clinical Trials

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Plymouth, MA

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Providence, RI

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Rosedale, NY

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Salem, VA

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Santa Fe, NM

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Santa Monica, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Sherman Oaks, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

South Miami, FL

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Springfield, MA

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Tacoma, WA

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Tucson, AZ

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Valencia, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Victoria, TX

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Voorhees, NJ

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Yorba Linda, CA

Renal Impairment Clinical Trial

A Study Evaluating the Pharmacokinetics of Doravirine in Participants With Severe Renal Impairment (MK-1439-051)

Status: Enrolling, Phase I
Updated: 3/18/2016

from

Orlando, FL

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Anaheim, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

Research Site

from

Apopka, FL

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Arlington, TX

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

El Paso, TX

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Fort Wayne, IN

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

Research Site

from

Hephzibah, GA

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Houston, TX

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Kansas City, MO

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Miami, FL

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Miami Gardens, FL

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Montebello, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Northridge, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Panorama City, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Sacramento, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Simi Valley, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Valencia, CA

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Warren, MI

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status: Enrolling, Phase III
Updated: 12/31/1969

Research Site

from

West Sacramento, CA

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Miami Gardens, FL

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Montebello, CA

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

North Platte, NE

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Prescott, AZ

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

San Luis Obispo, CA

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Tarzana, CA

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 10/10/2017

from

Bethlehem, PA

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 10/10/2017

from

Macon, GA

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 10/10/2017

from

Peoria, AZ

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 10/10/2017

Secondary Hyperparathyroidism-Chronic Kidney Disease Clinical Trial

from

Roseville, CA

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Status: Enrolling, Phase III
Updated: 12/31/1969

Secondary Hyperparathyroidism-Chronic Kidney Disease Clinical Trial

from

Detroit, MI

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Status: Enrolling, Phase III
Updated: 12/31/1969

Secondary Hyperparathyroidism-Chronic Kidney Disease Clinical Trial

from

Greenville, NC

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Status: Enrolling, Phase III
Updated: 12/31/1969

Secondary Hyperparathyroidism-Chronic Kidney Disease Clinical Trial

from

Los Angeles, CA

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Status: Enrolling, Phase III
Updated: 12/31/1969

Secondary Hyperparathyroidism-Chronic Kidney Disease Clinical Trial

from

New Haven, CT

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Status: Enrolling, Phase III
Updated: 12/31/1969

Secondary Hyperparathyroidism-Chronic Kidney Disease Clinical Trial

from

Orlando, FL

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Portland, OR

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Albany, NY

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Asheville, NC

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Birmingham, AL

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Cincinnati, OH

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Hawaiian Gardens, CA

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Jersey Shore, PA

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Kingsport, TN

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Metairie, LA

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Nashville, TN

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Philadelphia, PA

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

San Dimas, CA

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Tacoma, WA

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Topeka, KS

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Crystal Lake, IL

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Lynwood, CA

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Status: Enrolling, Phase III
Updated: 12/31/1969

Chronic Kidney Disease Mineral and Bone Disorder Clinical Trial

from

Michigan city, IN

Nephrology / Urology Clinical Trial

Ferric Citrate in ESRD Pilot Project

Status: Enrolling, Phase IV
Updated: 12/31/1969

US Renal Care- Scott Street

from

Houston, TX

Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease

Status: Enrolling, Phase
Updated: 12/31/1969

Purdue University Nutrition Science Department

from

West Lafayette, IN

Nephrology / Urology Clinical Trial

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Status: Enrolling, Phase II
Updated: 12/31/1969

Integris/Nazih Zudhi Transplant Institute

from

Oklahoma City, OK

Nephrology / Urology Clinical Trial

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Status: Enrolling, Phase II
Updated: 12/31/1969

University of Pennsylvania Health System, PCAM

from

Philadelphia, PA

IGA Nephropathy Clinical Trial

Efficacy and Safety of Atacicept in IgA Nephropathy

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Augusta, GA

IGA Nephropathy Clinical Trial

Efficacy and Safety of Atacicept in IgA Nephropathy

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Chattanooga, TN

Diabetic Nephropathies Clinical Trial

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Status: Enrolling, Phase I
Updated: 12/31/1969

Houston Clinical Research Associates

from

Houston, TX

Diabetic Nephropathies Clinical Trial

Status: Enrolling, Phase I
Updated: 12/31/1969

Science Advancing Medicine Clinical Research Center

from

San Antonio, TX

Hyperkalemia Clinical Trial

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Kansas City, KS

Hyperkalemia Clinical Trial

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Madison, WI

Hyperkalemia Clinical Trial

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Sofia,

Acute Kidney Injury Clinical Trial

Recovery After Dialysis-Requiring Acute Kidney Injury

Status: Enrolling
Updated: 12/31/1969

UCSF Medical Center Moffitt-Long Hospital

from

San Francisco, CA

End-Stage Renal Disease Clinical Trial

Anti-Cytokine Therapy for Hemodialysis InflammatION

Status: Enrolling, Phase II
Updated: 12/31/1969

University of Washington Kidney Research Institute

from

Seattle, WA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Albany, NY

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Anderson, SC

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Birmingham, AL

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Cincinnati, OH

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Des Moines, IA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Fairfax, VA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Federal Way, WA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Honolulu, HI

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Los Gatos, CA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Louisville, KY

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Maitland, FL

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Morehead City, NC

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Morganton, NC

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Norfolk, VA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Philadelphia, PA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Pittsburgh, PA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Plano, TX

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Saint Cloud, MN

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

San Dimas, CA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Spokane, WA

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Status: Enrolling, Phase III
Updated: 12/31/1969